3.80
前日終値:
$3.68
開ける:
$3.71
24時間の取引高:
571.43K
Relative Volume:
0.84
時価総額:
$229.60M
収益:
$40.37M
当期純損益:
$-119.72M
株価収益率:
-1.8626
EPS:
-2.0402
ネットキャッシュフロー:
$-135.06M
1週間 パフォーマンス:
+0.93%
1か月 パフォーマンス:
-8.21%
6か月 パフォーマンス:
-9.09%
1年 パフォーマンス:
+27.09%
Voyager Therapeutics Inc Stock (VYGR) Company Profile
名前
Voyager Therapeutics Inc
セクター
電話
857-259-5340
住所
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
VYGR
Voyager Therapeutics Inc
|
3.80 | 222.35M | 40.37M | -119.72M | -135.06M | -2.0402 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-02 | 開始されました | Citigroup | Buy |
| 2024-11-29 | 再開されました | Wedbush | Outperform |
| 2024-10-16 | 開始されました | Leerink Partners | Outperform |
| 2024-03-26 | 開始されました | Guggenheim | Buy |
| 2024-03-19 | 開始されました | H.C. Wainwright | Buy |
| 2024-03-07 | 開始されました | Citigroup | Buy |
| 2024-01-02 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-05-10 | 開始されました | Truist | Buy |
| 2023-03-10 | 開始されました | Oppenheimer | Outperform |
| 2021-10-07 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2021-02-03 | ダウングレード | BTIG Research | Buy → Neutral |
| 2021-02-03 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-12-24 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2020-12-23 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-11-10 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2020-11-10 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-03-19 | 開始されました | The Benchmark Company | Buy |
| 2020-02-06 | 開始されました | Oppenheimer | Outperform |
| 2018-11-15 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2018-09-10 | 再開されました | BTIG Research | Buy |
| 2018-09-10 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2018-06-04 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2018-03-12 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-02-02 | 開始されました | Morgan Stanley | Overweight |
| 2017-11-28 | 再開されました | Piper Jaffray | Overweight |
| 2017-10-31 | 開始されました | Robert W. Baird | Outperform |
| 2017-10-27 | 開始されました | Canaccord Genuity | Buy |
| 2017-10-23 | 繰り返されました | Stifel | Buy |
| 2017-10-12 | 開始されました | Raymond James | Outperform |
| 2017-08-17 | 開始されました | Evercore ISI | Outperform |
| 2017-07-28 | 再開されました | Stifel | Buy |
すべてを表示
Voyager Therapeutics Inc (VYGR) 最新ニュース
Voyager Therapeutics Inc. (VYGR) Q1 2026 Earnings: Narrowed Loss Meets Optimism in Gene Therapy PipelineEPS Consistency Score - Newser
Voyager Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ResponseNet Income Trends - Newser
Voyager Therapeutics (VYGR) Shares Rebound 4.76% as Biotech Sector Shows StrengthCrowd Risk Alerts - Newser
- Insider Monkey
What Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy Programs - Insider Monkey
Voyager Therapeutics (VYGR) accounting officer reports initial share and option holdings - Stock Titan
The one question every Voyager Therapeutics VYGR investor should ask Bullish Sentiment 20260510High Attention Stocks - Newser
VYGR (NASDAQ: VYGR) affiliate files Form 144 to sell 25,000 shares - Stock Titan
EcoR1 and Oleg Nodelman report 0 shares in Voyager (NASDAQ: VYGR) amendment - Stock Titan
Armistice Capital (VYGR) reports 3.5M shares, 5.87% stake in Voyager - Stock Titan
Voyager Therapeutics (NASDAQ: VYGR) affiliate files to sell 9,406 shares - Stock Titan
Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8 - Moomoo
TradingKey - TradingKey
VYGR Technical Analysis | Trend, Signals & Chart Patterns | VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) - ChartMill
Voyager presents preclinical data for Alzheimer’s gene therapy By Investing.com - Investing.com India
Voyager Therapeutics (VYGR) Reports Positive Findings for Alzhei - GuruFocus
VYGR Secures Mission Management Contract for ISS Research - GuruFocus
Voyager presents preclinical data for Alzheimer’s gene therapy - Investing.com UK
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026 - The Manila Times
Voyager Therapeutics Advances VY1706 Gene Therapy for Alzheimer's Disease with IND Application on Track for Q2 2026 - Quiver Quantitative
Voyager Therapeutics Presents Three-Month GLP Toxicology Data For VY1706 And Provides Updates On Gene Therapy Pipeline - marketscreener.com
CCORF Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $12 - Moomoo
The one question every Voyager Therapeutics (VYGR) investor should ask (Bullish Sentiment) 2026-05-10Social Momentum Signals - newser.com
Voyager Therapeutics Announces CFO Resignation and Finance Leadership Changes - TipRanks
Voyager Therapeutics (NASDAQ:VYGR) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Voyager Therapeutics Warns of Broad Risk Exposure and Uncertain Outlook in Latest SEC Filings - TipRanks
Voyager Therapeutics stock (US92916U1025): Q1 2026 results and pipeline updates drive sentiment - AD HOC NEWS
Voyager Therapeutics (VYGR) reports Q1 loss, misses revenue estimates - MSN
Voyager Therapeutics: Q1 Earnings Snapshot - theheraldreview.com
Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Alzheimer’s gene therapy moves toward human testing as cash lasts into 2028 - Stock Titan
Voyager Therapeutics (Nasdaq: VYGR) posts Q1 2026 loss and advances tau drugs - Stock Titan
Voyager Therapeutics (Nasdaq: VYGR) trims Q1 2026 loss, holds $171.7M cash - Stock Titan
Voyager Reports First Quarter 2026 Financial and Operating Results - marketscreener.com
VOYAGER THERAPEUTICS, INC. (VYGR) - MSN
Voyager Therapeutics CFO resigns; Robin Swartz takes financial charge - MSN
The key driver behind Voyager Therapeutics (VYGR) revenue growth | Q4 2025: Better Than ExpectedDividend Report - Newser
MSN Money - MSN
Voyager Therapeutics Inc (VYGR) - MSN
Voyager Therapeutics Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Voyager Therapeutics (VYGR) Stock: Support Breakdown Risk | Q4 2025: EPS Beats ForecastsEBITDA Estimate Trend - Newser
H.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR) - The Globe and Mail
H.C. Wainwright Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Voyager Therapeutics Inc (VYGR) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):